Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Hims & Hers Health Inc shares valued at $271,349 were purchased by Becklund Irene on May 22 ’25. At $53.51 per share, Becklund Irene acquired 5,071 shares.
Also, Okupe Oluyemi sold 11,581 shares, netting a total of over 697,462 in proceeds. Following the sale of shares at $60.22 each, the insider now holds 113,816 shares.
Before that, Dudum Andrew had sold 128,127 shares from its account. In a trade valued at $7,482,414, the Chief Executive Officer traded Hims & Hers Health Inc shares for $58.40 each. Upon closing the transaction, the insider’s holdings decreased to 128,127 shares, worth approximately $4.78 million.
As published in a research note from TD Cowen on April 29, 2025, Hims & Hers Health Inc [HIMS] has been rated down from a Buy to a Hold and the price target has been revised to $30. Analysts at Morgan Stanley downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal-weight”‘ outlook in a report released in mid February. As of January 10, 2025, Citigroup has decreased its “Neutral” rating to a “Sell” for HIMS. Earlier on January 07, 2025, BTIG Research initiated its rating. Their recommendation was “a Buy” for HIMS stock.
Analyzing HIMS Stock Performance
During the last five days, there has been a drop of approximately -8.64%. Over the course of the year, Hims & Hers Health Inc shares have jumped approximately 121.34%. Shares of the company reached a 52-week high of $72.98 on 02/19/25 and a 52-week low of $23.97 on 04/04/25.
Support And Resistance Levels for Hims & Hers Health Inc (HIMS)
According to the 24-hour chart, there is a support level at 50.97, which, if violated, would cause prices to drop to 48.43. In the upper region, resistance lies at 56.29. The next price resistance is at 59.07. RSI (Relative Strength Index) is 57.07 on the 14-day chart, showing neutral technical sentiment.
